Nuvation Bio Inc

NUVB

Company Profile

  • Business description

    Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

  • Contact

    1500 Broadway
    Suite 1401
    New YorkNY10036
    USA

    T: +1 332 208-6102

    https://www.nuvationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    273

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,586.7015.300.18%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,601.2656.950.24%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,160.47174.600.47%
NZX 50 Index12,563.4333.07-0.26%
S&P 5005,802.8239.19-0.67%
S&P/ASX 2008,360.9012.200.15%
SSE Composite Index3,348.3731.82-0.94%

Market Movers